Calcium dobesilate may improve hemorheology in patients undergoing coronary artery bypass grafting

Kazim Besirli1, Birsen Aydemir, Caner Arslan

  • 1Cardiovascular Surgery Department, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey. birsenay2001@yahoo.com

Insights

Calcium dobesilate improved erythrocyte flexibility in patients after myocardial revascularization. However, it did not significantly alter blood viscosity, oxidative stress markers, or clinical outcomes like CCS class.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hemodynamics

Background:

  • Calcium dobesilate is an angioprotective agent with antioxidant properties.
  • It enhances endothelial-derived vasodilator secretion.
  • Its effects in the postoperative period following myocardial revascularization remain under-investigated.

Purpose of the Study:

  • To evaluate the impact of calcium dobesilate on hemorheological parameters.
  • To assess changes in oxidant and antioxidant markers (reduced glutathione and malondialdehyde).
  • To determine effects in patients undergoing myocardial revascularization post-surgery.

Main Methods:

  • A study involving 134 patients undergoing coronary heart disease surgery.
  • Measurement of hemorheological, oxidant, and antioxidant parameters pre- and post-treatment.
  • A treatment group received 500 mg calcium dobesilate twice daily for three months; a control group did not.

Main Results:

  • Significant improvement in erythrocyte deformability index observed post-calcium dobesilate administration.
  • No significant changes noted in blood viscosity, glutathione (GSH), or malondialdehyde (MDA) levels.
  • Similar improvement in Canadian Cardiovascular Society (CCS) class observed in both treatment and control groups.

Conclusions:

  • Calcium dobesilate significantly enhances erythrocyte flexibility.
  • The drug did not demonstrate significant effects on blood viscosity or key oxidative stress markers.
  • Clinical improvement in CCS class was independent of calcium dobesilate treatment in this cohort.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...